0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Glomerulonephritis Caused by Chronic Hepatitis B Virus Infection: Treatment with Recombinant Human Alpha-Interferon

Mauricio Lisker-Melman, MD; David Webb, MD; Adrian M. Di Bisceglie, MD; Chris Kassianides, MD; Paul Martin, MD; Vinod Rustgi, MD; Jeanne G. Waggoner, BA; Yoon Park, RN; and Jay H. Hoofnagle, MD
[+] Article and Author Information

Requests for Reprints: Jay H. Hoofnagle, Liver Disease Section, Building 10, Room 4D-52, National Institutes of Health, Bethesda, MD 20892.

Current Author Addresses: Dr. Lisker-Melman: Instituto Nacional de la Nutricion, Department of Gastroenterology, Calle Vasco de Quiroga 15, 14000 Mexico D.F.

Dr. Webb: Wichita Nephrology Group, P.A. 818 North Emporia, Suite 310, Wichita, KS 67214.

Drs. Di Bisceglie, Kassianides, Martin, and Hoofnagle, and Ms. Waggoner and Ms. Park: Liver Diseases Section, Building 10, Room 4D-52, National Institutes of Health, Bethesda, MD 20892.

Dr. Rustgi: Department of Medicine, Fairfax Hospital, Falls Church, VA 22046.


Ann Intern Med. 1989;111(6):479-483. doi:10.7326/0003-4819-111-6-479
Text Size: A A A

Study Objectives: To assess the efficacy of alpha-interferon therapy in patients with hepatitis B virus (HBV)-related glomerulonephritis.

Design: Prospective, nonrandomized study.

Patients: Five patients with persistence of hepatitis B surface antigen, hepatitis B e antigen (HBeAg) and HBV DNA in serum for at least 6 months and histologic changes of chronic hepatitis on liver biopsy as well as persistent proteinuria of greater than 2 g/d and histologic changes of glomerulonephritis on renal biopsy.

Interventions: Patients received a 4-month course of recombinant human alpha-interferon (alfa-2b) beginning at a dose of 5 million units administered subcutaneously each day.

Results: Serum levels of HBV DNA decreased in all patients and fell to undetectable levels during treatment in four of five patients. In the four responding patients, serum HBeAg disappeared, aminotransferases fell into the normal range, and a follow-up liver biopsy showed an improvement in the hepatocyte necrosis and inflammation. Urine protein excretion also decreased during treatment. In the four responding patients, urine protein excretion gradually fell to less than 1 g/d and serum albumin levels rose into the normal range. Resolution of the biochemical and serologic evidence of chronic hepatitis and glomerulonephritis was accompanied by disappearance of signs and symptoms of liver and kidney disease.

Conclusions: A high proportion of patients with HBV-related glomerulonephritis will respond to a 4-month course of alpha-interferon with a clinical, biochemical, and serologic remission.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)